- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07942350
AI-Powered Chatbot Integrated With Wearable-Derived Data for Promoting Mental Health Among Finnish Higher Education Students
Mental health problems among adolescents and young adults have increased globally, underscoring the urgent need for accessible, preventive, and systemic approaches to promoting student mental health. This pilot study aims to evaluate the feasibility, conversational quality, and preliminary effectiveness of an AI-powered chatbot integrated with wearable-derived physiological data intervention to provide personalized and timely mental health support for Finnish higher education students. The study explores how real-time stress indicators, such as heart rate variability (HRV), can inform the chatbot's adaptive and proactive interactions to promote students' mental health in daily life.
The study setting will be the Faculty of Medicine, University of Turku in Finland. A total of 15-20 participants will be recruited with convenience sampling for this study. The inclusion criteria for participants are: 1) enrolled students at the Faculty of Medicine, 2) voluntary and consenting, 3) Finnish-speaking, 4) having a smart phone (Android/iOS), and 5) having none to mild levels of psychological distress. Participants who self-report a diagnosis of mental health disorder, or having an acute treatment for mental health will be excluded.
The intervention in this study consists of 4-week daily use of a AI-powered chatbot. In addition to access to the chatbot, a wearable device will be given to each participant to collect physiological data related to their stress (HRV), physical activity and sleep. At the end of week 2 and 3 of the study, participants will receive a personalized report summarizing the data collected by the device. Throughout the intervention period, the research assistant will contact participants once a week to ensure their well-being. At the end of the study, an interview will be arranged with each participant.
The study data includes the conversations with the chatbot, physiological data from the wearable device, daily stress questions, background information questionnaire, Depression Anxiety Stress Scale (DASS-21) (at the beginning of the intervention and at weeks 2 and 4), Chatbot Usability Questionnaire (CUQ) (at weeks 2 and 4) and an end-of-study semi-structured interview.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Anna Axelin
- Numero di telefono: +358405029905
- Email: anmaax@utu.fi
Luoghi di studio
-
-
-
Turku, Finlandia
- Reclutamento
- University of Turku
-
Contatto:
- Anna Axelin
- Numero di telefono: +358405029905
- Email: anmaax@utu.fi
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Study population consists of higher education students.
Descrizione
Inclusion Criteria:
- enrolled students at the Faculty of Medicine (bachelor's, master's, or doctoral level students)
- voluntary and consenting
- Finnish-speaking (native speaker or enrolled in a Finnish study program)
- having a smart phone (Android/iOS)
- having none to mild levels of psychological distress
Exclusion Criteria:
- self-reported diagnosis of mental health disorder, or having an acute treatment for mental health
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: OTHER
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Higher education students
|
Daily use of an AI-powered chatbot and a wearable device to collect physiological data related to stress, physical activity and sleep. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Eligibility of participants
Lasso di tempo: 4 weeks
|
The number of individuals screened, the proportion that meets the inclusion criteria, and the main reasons for exclusion will be documented to assess the appropriateness and practicality of the eligibility criteria. |
4 weeks
|
|
Recruitment and retention of participants
Lasso di tempo: 4 weeks
|
The number of participants enrolled, the proportion completing the whole intervention as well as assessments, and attrition rates will be recorded to evaluate recruitment efficiency and participant retention. |
4 weeks
|
|
Engagement of the participants
Lasso di tempo: 4 weeks
|
Quantitative indicators that include the frequency of chatbot interactions, average session length, and response rates will be analyzed to assess adherence to study procedures and sustained engagement over time. |
4 weeks
|
|
Technical performance of the chatbot
Lasso di tempo: 4 weeks
|
System reliability will be examined through logs of technical errors, data integration issues, and chatbot downtime events, providing insights into the stability and operational consistency of the intervention platform. |
4 weeks
|
|
Safety of the chatbot
Lasso di tempo: 4 weeks
|
It will be assessed whether the chatbot's interactions are free from harm and whether it can appropriately identify and manage high-risk user input. Evaluation focuses on the chatbot's ability to detect and respond to indications of severe distress or crisis, such as expressions of self-harm, suicidal ideation, abuse, or other high-risk situations. Following the MHealth-EVAL framework (Chen et al., 2024), responses will be annotated using a binary scale, where "0" indicates the presence of harmful or unsafe content or failure to address crisis cues appropriately, and "1" indicates a safe and supportive response. |
4 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Psychological distress
Lasso di tempo: 4 weeks
|
Psychological distress will be assessed using the Depression Anxiety Stress Scales-21 (DASS-21), which is a 21-item self-report instrument measuring three dimensions of negative emotional states: depression, anxiety, and general stress. Each subscale includes seven items rated on a 4-point Likert scale (0-3), with higher scores indicating greater symptom severity. DASS-21 will be administered before, at two weeks, and after the intervention to assess potential changes in participants' psychological stress. |
4 weeks
|
|
Behavioral change and health literacy
Lasso di tempo: 4 weeks
|
At the end of the 4-week intervention, semi-structured interviews will be conducted with each participant individually to gain an in-depth understanding of their experiences with the chatbot as well as any behavioral changes they perceived during the study. In addition, the participants' understanding of AI health literacy will be discussed. |
4 weeks
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- TY/2154/2025
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Dataset may be made available for secondary use through the international open science repository Dryad. Identifiers will be removed from the dataset to ensure that individual participants cannot be identified. Secondary use of the data requires a permission process that adheres to established research ethics principles.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .